Advanced search
Publication Cover
OncoImmunology Volume 4, 2015 - Issue 8
Submit an article Journal homepage
3,298
Views
72
CrossRef citations to date
0
Altmetric
Original Research

Several immune escape patterns in non-Hodgkin's lymphomas

Camille LaurentInstitut Universitaire du Cancer-Oncopole de Toulouse; Toulouse, France;Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037; Toulouse, France;Université Toulouse III Paul-Sabatier; Toulouse, France;ERL 5294 CNRS; Toulouse, France;Programme Hospitalo-Universitaire en Cancérologie CAPTOR; Toulouse, France;Institut Carnot Lymphome CALYM; Toulouse, France;Laboratoire d'Excellence ‘TOUCAN’; Toulouse, FranceCorrespondence[email protected]
,
Konstantina CharmpiLaboratoire d'Excellence ‘TOUCAN’; Toulouse, France;Laboratoire Jean Kuntzmann; CNRS UMR5224; Grenoble, France
,
Pauline GravelleInstitut Universitaire du Cancer-Oncopole de Toulouse; Toulouse, France;Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037; Toulouse, France;Université Toulouse III Paul-Sabatier; Toulouse, France;ERL 5294 CNRS; Toulouse, France;Programme Hospitalo-Universitaire en Cancérologie CAPTOR; Toulouse, France;Institut Carnot Lymphome CALYM; Toulouse, France;Laboratoire d'Excellence ‘TOUCAN’; Toulouse, France
,
Marie TosoliniCentre de Recherches en Cancérologie de Toulouse; INSERM UMR1037; Toulouse, France;Université Toulouse III Paul-Sabatier; Toulouse, France;ERL 5294 CNRS; Toulouse, France;Programme Hospitalo-Universitaire en Cancérologie CAPTOR; Toulouse, France;Institut Carnot Lymphome CALYM; Toulouse, France;Laboratoire d'Excellence ‘TOUCAN’; Toulouse, France
,
Camille FranchetInstitut Universitaire du Cancer-Oncopole de Toulouse; Toulouse, France
,
Loïc YsebaertInstitut Universitaire du Cancer-Oncopole de Toulouse; Toulouse, France;Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037; Toulouse, France;Université Toulouse III Paul-Sabatier; Toulouse, France;ERL 5294 CNRS; Toulouse, France;Programme Hospitalo-Universitaire en Cancérologie CAPTOR; Toulouse, France;Institut Carnot Lymphome CALYM; Toulouse, France;Laboratoire d'Excellence ‘TOUCAN’; Toulouse, France
,
Pierre BroussetInstitut Universitaire du Cancer-Oncopole de Toulouse; Toulouse, France;Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037; Toulouse, France;Université Toulouse III Paul-Sabatier; Toulouse, France;ERL 5294 CNRS; Toulouse, France;Programme Hospitalo-Universitaire en Cancérologie CAPTOR; Toulouse, France;Institut Carnot Lymphome CALYM; Toulouse, France;Laboratoire d'Excellence ‘TOUCAN’; Toulouse, France
,
Alexandre BidautInstitut de Recherche Pierre Fabre; Castres, France
,
Bernard YcartLaboratoire d'Excellence ‘TOUCAN’; Toulouse, France;Laboratoire Jean Kuntzmann; CNRS UMR5224; Grenoble, France
&
Jean-Jacques FourniéCentre de Recherches en Cancérologie de Toulouse; INSERM UMR1037; Toulouse, France;Université Toulouse III Paul-Sabatier; Toulouse, France;ERL 5294 CNRS; Toulouse, France;Programme Hospitalo-Universitaire en Cancérologie CAPTOR; Toulouse, France;Institut Carnot Lymphome CALYM; Toulouse, France;Laboratoire d'Excellence ‘TOUCAN’; Toulouse, France
 show all
Article: e1026530 | Received 03 Feb 2015, Accepted 27 Feb 2015, Published online: 25 Jul 2015

Citations (72)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Agnieszka Karczmarczyk, Maciej Korpysz, Sylwia Bilska, Joanna Purkot, Marek Hus & Krzysztof Giannopoulos. (2022) Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients. Cancer Management and Research 14, pages 1267-1281.
Read now
Yuyang Tian, Lianqiao Li, Guoqiang Lin, Yan Wang, Li Wang, Qian Zhao, Youdong Hu, Hongmei Yong, Yan Wan & Yanming Zhang. (2021) lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p. Leukemia & Lymphoma 62:7, pages 1574-1584.
Read now
Uffe Klausen, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Shamaila Munir Ahmad, Anne Ortved Gang, Evelina Martinenaite, Stine Emilie Weis-Banke, Marie Fredslund Breinholt, Guy Wayne Novotny, Julie Westerlin Kjeldsen, Morten Orebo Holmström, Lone Bredo Pedersen, Christian Bjørn Poulsen, Per Boye Hansen, Özcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Møller Pedersen & Mads Hald Andersen. (2021) An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. OncoImmunology 10:1.
Read now
San Krittikarux, Kitsada Wudhikarn, Nichthida Tangnuntachai, Thamathorn Assanasen, Narittee Sukswai, Thiti Asawapanumas & Chantiya Chanswangphuwana. (2020) The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma. Leukemia & Lymphoma 61:14, pages 3395-3403.
Read now
Tarsheen K. Sethi, Alexandra E. Kovach, Natalie S. Grover, Li-Ching Huang, Laura A. Lee, Samuel M. Rubinstein, Yang Wang, David S. Morgan, John P. Greer, Steven I. Park, Mary Ann Thompson-Arildsen, Ashwini Yenamandra, Cindy L. Vnencak-Jones & Nishitha M. Reddy. (2019) Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 60:12, pages 2880-2889.
Read now
Cédric Rossi, Pauline Gravelle, Emilie Decaup, Julie Bordenave, Mary Poupot, Marie Tosolini, Don-Marc Franchini, Camille Laurent, Renaud Morin, Jean-Michel Lagarde, Loïc Ysebaert, Laetitia Ligat, Christine Jean, Ariel Savina, Christian Klein, Alba Matas Céspedes, Patricia Perez-Galan, Jean-Jacques Fournié & Christine Bezombes. (2019) Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. OncoImmunology 8:3.
Read now
Pauline Gravelle, Sarah Péricart, Marie Tosolini, Bettina Fabiani, Paul Coppo, Nadia Amara, Alexandra Traverse-Gléhen, Nathalie Van Acker, Pierre Brousset, Jean-Jacques Fournie & Camille Laurent. (2018) EBV infection determines the immune hallmarks of plasmablastic lymphoma. OncoImmunology 7:10.
Read now
Shamaila Munir Ahmad, Evelina Martinenaite, Morten Holmström, Mia Aaboe Jørgensen, Özcan Met, Claudia Nastasi, Uffe Klausen, Marco Donia, Lars Møller Pedersen, Lars Munksgaard, Niels Ødum, Anders Woetmann, Inge Marie Svane & Mads Hald Andersen. (2018) The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. OncoImmunology 7:2.
Read now
Cristina Ilcus, Cristina Bagacean, Adrian Tempescul, Cristian Popescu, Andrada Parvu, Mihai Cenariu, Corina Bocsan & Mihnea Zdrenghea. (2017) Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy 10, pages 2349-2363.
Read now
Huanbin Wang, Han Yao, Chushu Li, Lunxi Liang, Yao Zhang, Hubing Shi, Chongzhi Zhou, Yingxuan Chen, Jing-Yuan Fang & Jie Xu. (2017) PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. OncoImmunology 6:7.
Read now
Pauline Gravelle, Catherine Do, Camille Franchet, Sabina Mueller, Lucie Oberic, Loïc Ysebaert, Luigi Maria Larocca, Stefan Hohaus, Marie-Noëlle Calmels, François-Xavier Frenois, Robert Kridel, Randy D. Gascoyne, Guy Laurent, Pierre Brousset, Salvatore Valitutti & Camille Laurent. (2016) Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement. OncoImmunology 5:10.
Read now
Marie Tosolini, Christelle Algans, Frédéric Pont, Bernard Ycart & Jean-Jacques Fournié. (2016) Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. OncoImmunology 5:7.
Read now

Articles from other publishers (60)

Jie Zhou, Min Xu, ZhaoZhao Chen, LinLin Huang, ZhuoLin Wu, ZhongPei Huang & Lin Liu. (2023) circ_SPEF2 Regulates the Balance of Treg Cells by Regulating miR-16-5p/BACH2 in Lymphoma and Participates in the Immune Response. Tissue Engineering and Regenerative Medicine 20:7, pages 1145-1159.
Crossref
Chengbo Xu, Hongfang Xu & Baimei Liu. (2023) Head and neck squamous cell carcinoma-specific prognostic signature and drug sensitive subtypes based on programmed cell death-related genes. PeerJ 11, pages e16364.
Crossref
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masakatsu Tsurusaki, Takuya Nakai, Michiie Sakamoto, Kazuto Nishio & Masatoshi Kudo. (2023) Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations. Liver Cancer, pages 1-21.
Crossref
Carla Faria, Fabien Gava, Pauline Gravelle, Juan Garcia Valero, Celia Dobaño-López, Nathalie Van Acker, Cathy Quelen, Gael Jalowicki, Renaud Morin, Cédric Rossi, Jean-Michel Lagarde, Jean-Jacques Fournié, Loïc Ysebaert, Camille Laurent, Patricia Pérez-Galán & Christine Bezombes. (2023) Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine. Journal for ImmunoTherapy of Cancer 11:10, pages e007156.
Crossref
Ferran Araujo-Ayala, Cèlia Dobaño-López, Juan García Valero, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Neus Serrat, Heribert Playa-Albinyana, Rubén Giménez, Elías Campo, Jean-Michel Lagarde, Armando López-Guillermo, Eva Gine, Dolors Colomer, Christine Bezombes & Patricia Pérez-Galán. (2023) A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses. Leukemia 37:6, pages 1311-1323.
Crossref
Catherine Zilberg, James Guy Lyons, Ruta Gupta & Diona Lee Damian. (2023) The Immune Microenvironment in Basal Cell Carcinoma. Annals of Dermatology 35:4, pages 243.
Crossref
A. Brunner, E. Willenbacher, W. Willenbacher, B. Zelger, P. Zelger, C.W. Huck & J.D. Pallua. (2023) Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 285, pages 121940.
Crossref
Juan‐Pablo Cerapio, Marion Perrier, Fréderic Pont, Camille Laurent, Stéphane Bertani & Jean‐Jacques Fournie. (2022) Single-cell differentiation trajectories define early stages of a human cutaneous T-cell lymphoma. Exploration of Immunology, pages 185-199.
Crossref
Akio Onishi, Shigeo Fuji, Shigehisa Kitano, Akiko Miyagi Maeshima, Kinuko Tajima, Junko Yamaguchi, Ichiro Kawashima, Akihisa Kawajiri, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Keiji Okinaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Wataru Munakata, Dai Maruyama, Kensei Tobinai & Takahiro Fukuda. (2022) Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia–lymphoma. Annals of Hematology 101:4, pages 799-810.
Crossref
Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang & Yong Xia. (2022) Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology & Oncology 15:1.
Crossref
Roberto Tamma, Giuseppe Ingravallo, Tiziana Annese, Francesco Gaudio, Tommasina Perrone, Pellegrino Musto, Giorgina Specchia & Domenico Ribatti. (2022) Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. Journal of Clinical Medicine 11:5, pages 1257.
Crossref
Manal Mohamed Saber. (2022) Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma. Antibodies 11:1, pages 15.
Crossref
David Qualls & Gilles Salles. (2022) Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 107:1, pages 19-34.
Crossref
Andriani Charalambous & Mark-Alexander Schwarzbich. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 42 .
Wanying Zhao, Yuanzheng Liang & Liang Wang. (2021) Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. Aging Pathobiology and Therapeutics 3:4, pages 84-94.
Crossref
Marijana Nesic, Mads Sønderkær, Rasmus Froberg Brøndum, Tarec Christoffer El-Galaly, Inge Søkilde Pedersen, Martin Bøgsted & Karen Dybkær. (2021) The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. BMC Cancer 21:1.
Crossref
Wenqi Zhang, Yanfeng Fan, Meng Li, Linqi Yang, Zhenya Zhang & Lihong Liu. (2021) Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL). Disease Markers 2021, pages 1-8.
Crossref
Ichiro Hanamura, Susumu Suzuki, Akinobu Ota, Satsuki Murakami, Akira Satou, Taishi Takahara, Sivasundaram Karnan, Vu Quang Lam, Ayano Nakamura, Souichi Takasugi, Kazuhiro Yoshikawa, Shogo Banno, Masayuki Ejiri, Toyonori Tsuzuki, Yoshitaka Hosokawa, Ryuzo Ueda & Akiyoshi Takami. (2021) The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma. Hemato 2:2, pages 368-381.
Crossref
Ferran Araujo‐Ayala, Patricia Pérez‐Galán & Elias Campo. (2021) Vulnerabilities in the tumor and microenvironment in follicular lymphoma. Hematological Oncology 39:S1, pages 83-87.
Crossref
T. J. M. Kuijpers, J. C. S. Kleinjans & D. G. J. Jennen. (2021) From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics. Scientific Reports 11:1.
Crossref
Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell & Colm Keane. (2021) PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells 10:5, pages 1152.
Crossref
Cèlia Dobaño-López, Ferran Araujo-Ayala, Neus Serrat, Juan G. Valero & Patricia Pérez-Galán. (2021) Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. Cancers 13:4, pages 641.
Crossref
Philippe ArmandAnn JanssensGiuseppe GrittiJohn Radford, John TimmermanAntonio Pinto, Santiago Mercadal VilchezPeter Johnson, David Cunningham, John P. LeonardScott J. RodigPatricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang & Stephen M. Ansell. (2021) Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood 137:5, pages 637-645.
Crossref
Jaco A. C. van Bruggen, Anne W. J. Martens, Sanne H. Tonino & Arnon P. Kater. (2020) Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 12:12, pages 3837.
Crossref
Cédric Rossi, Marie Tosolini, Pauline Gravelle, Sarah Pericart, Salim Kanoun, Solene Evrard, Julia Gilhodes, Don-Marc Franchini, Nadia Amara, Charlotte Syrykh, Pierre Bories, Lucie Oberic, Loïc Ysebaert, Laurent Martin, Selim Ramla, Philippine Robert, Claire Tabouret-Viaud, René-Olivier Casasnovas, Jean-Jacques Fournié, Christine Bezombes & Camille Laurent. (2020) Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica 107:1, pages 221-230.
Crossref
Yukari Kobayashi, Yoshihiro Kushihara, Noriyuki Saito, Shigeo Yamaguchi & Kazuhiro Kakimi. (2020) A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions. Cancer Science 111:11, pages 4031-4040.
Crossref
John Apostolidis, Ayman Sayyed, Mohammed Darweesh, Panayotis Kaloyannidis & Hani Al Hashmi. (2020) Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma. Journal of Immunology Research 2020, pages 1-18.
Crossref
Anna Szumera-Ciećkiewicz, Jan Poleszczuk, Olga Kuczkiewicz-Siemion, Ewa Paszkiewicz-Kozik, Grzegorz Rymkiewicz, Kamil Sokół, Anita Borysiuk, Martyna Kotarska, Monika Kawecka, Daria Owczarek, Beata Pytlak, Jan Walewski & Monika Prochorec-Sobieszek. (2020) PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma. Pathology - Research and Practice 216:10, pages 153096.
Crossref
Xue-wen Zhang, Xi-wen Bi, Pan-pan Liu, Ze-long Liu, Man Nie, Hang Yang, De-xin Lei, Yi Xia, Wen-qi Jiang & Wei-an Zeng. (2020) Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma. Frontiers in Oncology 10.
Crossref
Loic Ysebaert & Franck Morschhauser. (2020) Immunomodulatory Agents in Follicular Lymphoma. Hematology/Oncology Clinics of North America 34:4, pages 715-726.
Crossref
Massimo Giuliani & Alessandro Poggi. (2020) Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells 9:7, pages 1578.
Crossref
Melissa Alame, Marion Pirel, Valérie Costes-Martineau, Luc Bauchet, Michel Fabbro, Alicia Tourneret, Laura De Oliveira, Luc Durand, Pascal Roger, Samia Gonzalez, Valère Cacheux, Valérie Rigau & Vanessa Szablewski. (2019) Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Virchows Archiv 476:6, pages 891-902.
Crossref
Colm Keane, Soi C. Law, Clare Gould, Simone BirchMuhammed B. SabdiaLilia Merida de LongGayathri ThillaiyampalamEmad AbroJoshua W. TobinXiaohong TanZijun Y. Xu-Monette, Ken H. YoungGrace GiffordSara GabreilliWilliam S. StevensonAnthony GillDipti Talaulikar, Sanjiv Jain, Annette HernandezSarah-Jane HallidayRobert Bird, Donna CrossMark Hertzberg & Maher K. Gandhi. (2020) LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances 4:7, pages 1367-1377.
Crossref
Nahum Puebla-Osorio, Paolo Strati & Sattva S. Neelapu. 2020. Follicular Lymphoma. Follicular Lymphoma 65 82 .
Christelle Vincent-Fabert, Lilian Roland, Ursula Zimber-Strobl, Jean Feuillard & Nathalie Faumont. (2019) Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. Cell Communication and Signaling 17:1.
Crossref
Mixue Xie, Xianbo Huang, Xiujin Ye & Wenbin Qian. (2019) Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. International Immunopharmacology 77, pages 105999.
Crossref
Moussab Damlaj, Mohammed Alzayed, Bader Alahmari, Ayman Alhejazi, Ahmed Alaskar & Mohsen Alzahrani. (2019) Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. Clinical Lymphoma Myeloma and Leukemia 19:10, pages e559-e563.
Crossref
Valeria Martini, Luca Aresu, Fulvio Riondato, Laura Marconato, Marzia Cozzi, Damiano Stefanello & Stefano Comazzi. (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. Research in Veterinary Science 125, pages 130-135.
Crossref
Qing-Ming Wang, Guang-Yu Lian, Yuan Song, Yan-Fang Huang & Yi Gong. (2019) LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sciences 231, pages 116335.
Crossref
Frédérique Larousserie, Diakho Kebe, Tony Huynh, Anne Audebourg, Jérôme Tamburini, Benoît Terris & Odile Devergne. (2019) Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis. Frontiers in Oncology 9.
Crossref
Christelle Vincent-Fabert, Isabelle Soubeyran, Valérie Velasco, Marie Parrens, Robin Jeannet, Emilie Lereclus, Nathalie Gachard, Jean Feuillard & Nathalie Faumont. (2019) Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells. Cellular & Molecular Immunology 16:6, pages 621-624.
Crossref
Ling Li, Ruifang Sun, Yi Miao, Thai Tran, Lisa Adams, Nathan Roscoe, Bing Xu, Ganiraju C. Manyam, Xiaohong Tan, Hongwei Zhang, Min Xiao, Alexandar Tzankov, Carlo Visco, Karen Dybkaer, Govind Bhagat, Wayne Tam, Eric D. Hsi, J.Han van Krieken, Hua You, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Miguel A. Piris, Mingzhi Zhang, Jane N. Winter, L.Jeffrey Medeiros, George Z. Rassidakis, Christine A. Vaupel, Yong Li, Naveen Dakappagari, Zijun Y. Xu-Monette & Ken H. Young. (2019) PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology 32:6, pages 741-754.
Crossref
Ziju Y. Xu-Monette, Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, Raul Torres-Ruiz, Ganiraju C. Manyam, Carlo Visco, Yi Miao, Xiaohong Tan, Hongwei Zhang, Alexandar Tzankov, Jing Wang, Karen Dybkær, Wayne Tam, Hua You, Govind Bhagat, Eric D. Hsi, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Miguel A. Piris, J. Han van Krieken, Jane N. Winter, Jason R. Westin, Lan V. Pham, L. Jeffrey Medeiros, George Z. Rassidakis, Yong Li, Gordon J. Freeman & Ken H. Young. (2019) Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research 7:4, pages 644-657.
Crossref
Moo-Kon Song, Byeong-Bae Park & Jieun Uhm. (2019) Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma. International Journal of Molecular Sciences 20:6, pages 1326.
Crossref
Sarah E. Josefsson, Klaus Beiske, Yngvild N. Blaker, Mette S. Førsund, Harald Holte, Bjørn Østenstad, Eva Kimby, Hakan Köksal, Sébastien Wälchli, Baoyan Bai, Erlend B. Smeland, Ronald Levy, Arne Kolstad, Kanutte Huse & June H. Myklebust. (2019) TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunology Research 7:3, pages 355-362.
Crossref
Yuka Suzuki, Ayako Sakakibara, Kazuyuki Shimada, Satoko Shimada, Eri Ishikawa, Shigeo Nakamura, Seiichi Kato, Taishi Takahara, Naoko Asano, Akira Satou & Kei Kohno. (2019) Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma. Pathology International 69:1, pages 13-20.
Crossref
Yazeed Sawalha & Anjali Advani. 2019. Immune Checkpoint Inhibitors in Cancer. Immune Checkpoint Inhibitors in Cancer 169 191 .
Ting Martin Ma, Hyunseok Kang, Steven P. Rowe & Ana P. Kiess. (2018) Response to R-CHOP in HPV-related squamous cell carcinoma of base of tongue: a case report. Cancers of the Head & Neck 3:1.
Crossref
Hyun Jung Kwon, Jeong Mi Yang, Jeong-Ok Lee, Jong Seok Lee & Jin Ho Paik. (2018) Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. Journal of Translational Medicine 16:1.
Crossref
Sarah Péricart, Marie Tosolini, Pauline Gravelle, Cédric Rossi, Alexandra Traverse-Glehen, Nadia Amara, Camille Franchet, Elodie Martin, Christine Bezombes, Guy Laurent, Pierre Brousset, Jean-Jacques Fournié & Camille Laurent. (2018) Profiling Immune Escape in Hodgkin’s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers 10:11, pages 415.
Crossref
Uffe Klausen, Staffan Holmberg, Morten Orebo Holmström, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Inge Marie Svane & Mads Hald Andersen. (2018) Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Frontiers in Immunology 9.
Crossref
Deepika Kumar & Mina L. Xu. (2018) Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers in Oncology 8.
Crossref
Zijun Y. Xu-MonetteJianfeng Zhou & Ken H. Young. (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:1, pages 68-83.
Crossref
Kirill Viktorovich Lepik. (2018) Immune Checkpoint Inhibitors in the Treatment of Lymphomas. Clinical oncohematology 11:4, pages 303-312.
Crossref
Jordi Ochando & Mounia S. Braza. (2017) T follicular helper cells: a potential therapeutic target in follicular lymphoma. Oncotarget 8:67, pages 112116-112131.
Crossref
Pauline Gravelle, Barbara Burroni, Sarah Péricart, Cédric Rossi, Christine Bezombes, Marie Tosolini, Diane Damotte, Pierre Brousset, Jean-Jacques Fournié & Camille Laurent. (2017) Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 8:27, pages 44960-44975.
Crossref
Fengyuan Che, Xueyuan Heng, Haiyan Zhang, Quanping Su, Baoxue Zhang, Yanying Chen, Zhaohong Zhang, Yifeng Du & Lijuan Wang. (2017) Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. Cancer Immunology, Immunotherapy 66:6, pages 717-729.
Crossref
Barbara Burroni, Chlo? Broudin, Diane Damotte & Camille Laurent. (2017) Les immune-checkpoints dans les h?mopathies. Annales de Pathologie 37:1, pages 101-110.
Crossref
Pierre Sujobert, Gilles Salles & Emmanuel Bachy. (2016) Molecular Classification of Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1163-1177.
Crossref
Laura Bounaix, Mohammed Bendouda, Jacques-Olivier Bay & Richard Lemal. (2016) Utilisation des inhibiteurs de PD-1 dans les h?mopathies lympho?des. Bulletin du Cancer 103, pages S160-S163.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.